|
🐜
|
PROGRESS‐AD: a phase 2 study to evaluate efficacy and safety of GSK4527226 (AL101), an anti‐sortilin monoclonal antibody, in patients with early Alzheimer’s disease
20 auth.
Sandra Machlitt‐Northen,
Azza Abdelkarim,
Christine Bailey,
Balasubrahmanyam Budda,
Stéphanie Bombois,
Bruce J Brew,
Dimitra Brintziki,
Brady Burgess,
Sharon Cohen,
Gopinath Ganji,
...
Massimiliano Germani,
Dave Inman,
Tharaka Jayabalan,
C. J. Mummery,
Lovingly Park,
Christine Parker,
Gary Romano,
Martin Sadowski,
Giacomo Salvadore,
Robert Y. K. Lai
|
0 |
2024 |
0
🐜
|
